We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Selonsertib

News List

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) drugs
May 09, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH).
Gilead’s selonsertib flunks another NASH phase 3 fiercebiotech
April 28, 2019
Gilead’s NASH candidate selonsertib has disappointed in yet another phase 3 trial. This time, two different doses of the drug did worse than placebo at reducing scarring in patients with bridging fibrosis—also called stage 3 fibrosis—from nonalcoholic ste
Study of Selonsertib in Bridging Fibrosis Study Does Not Meet Primary Endpoint americanpharmaceuticalreview
April 26, 2019
Gilead Sciences announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational ...
Phase 3 STELLAR-4 Study of Selonsertib Did Not Meet Primary Endpoint americanpharmaceuticalreview
February 13, 2019
Gilead Sciences announced STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1).....